Jiangsu Hengrui Medicine Co. Ltd. Gains FDA Approval for Cancer Drug

Published: Dec 20, 2011

December 20, 2011 -- Jiangsu Hengrui Medicine has been granted FDA approval for Irinotecan, an anti-cancer drug that is usually prescribed as part of a drug cocktail for colon cancer. According to Hengrui, the approval is the first given to a China company for an injected drug. The company said it plans to use the experience of its first FDA approval to accelerate plans for US and European acceptance of other drugs in its portfolio. More details....

Stock Symbol: (SHA: 600276)

Back to news